Application of Erxian Decoction combined with alpha-blocker in the treatment of late-onset hypogonadism in males with lower urinary tract symptoms

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026559

Enrollment

Unknown

Registered

2019-10-14

Start date

2019-10-22

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late-onset hypogonadism in males

Interventions

observation group:Erxian Decoction combined with Tamsulosin Hydrochloride Sustained Release Tablets

control group:Tamsulosin Hydrochloride Sustained Release Tablets

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Aged over 50 years, male. 2. AMS >= 27 points. 3. IPSS > 7 points. 4. TT <= 11.5nmol/L; TSI<= 2.8nmol/IU. 5. Total Testosterone <= 11.5nmol/L, Testosterone Secretion Index <= 2.8nmol/IU.

Exclusion criteria

Exclusion criteria: 1. Pituitary or testicular organic diseases. 2. Prostate cancer or prostate specific antigen (PSA) >= 4 ug/L did not exclude the high risk of prostate cancer. 3. Patients with polycythemia. 4. Patients with severe sleep apnea syndrome. 5. Pelvic surgery, major trauma or neurogenic bladder. 6. Severe obesity, diabetes, sleep disorders and urinary tract infections. 7. Patients with severe heart, liver, kidney and hematopoietic diseases. 8. Patients with severe mental illness. 9. Subjects are participating in other clinical trials or have used sex hormones or drugs that affect sex hormone levels in the past three months. 10. Those who are using alpha receptor blockers, PDE-5 inhibitors or other drugs to improve LUTS.

Design outcomes

Primary

Measure	Time frame
Aging male symptoms, AMS;International prostate symptom score, IPSS;Quality of life score, QOL;Sex hormone;Prostate volume and residual urine volume;Maximum urinary flow rate, Qmax;	—

Secondary

Measure	Time frame
International index of erectile function, IIEF-5;	—

Countries

China

Contacts

Public ContactZhang Qifeng

Guilin people's hospital

lanwind@163.com+86 15107733166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026